Exact Sciences Corporation

The company provides cancer screening and diagnostic test products globally. They offer Cologuard, a non-invasive stool-based DNA test for colorectal cancer detection. Other tests include Oncotype DX Breast Recurrence Score Test and Colon Recurrence Score Test. OncoExTra Test is used for tumor profiling in patients with advanced cancer. The company also offers Covid-19 testing services. Pipeline products aim to enhance Cologuards performance and develop blood-based tests. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Wisconsin.

Overview

Sector

Healthcare

Target Price

0.0 USD

Current Price

104.9 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (87.66) is higher than the sector mean.
EV/EBITDA (1207.68) is significantly higher than the sector mean (36.02).
EV/EBIT (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.55%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	1207.7
Price/Free Cash Flow'	56.1
ROIC	10.0%
Net Debt/EBITDA	87.7

Exact Sciences Corporation

Overview

Strengths

Weaknesses

Key Financial Data